Clinical trial
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
NCT05736835 is registered in ClinicalTrials.gov with CyanVac LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
- Lead sponsor
- CyanVac LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 21, 2023
- Completion date
- December 16, 2025
- Enrollment
- 227 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.